Applications of 6-Hydroxy-7-Methoxy-3,4-Dihydroquinazolin-4-One in Industrial Manufacturing

As a dedicated manufacturer of advanced chemical raw materials, we supply 6-Hydroxy-7-Methoxy-3,4-Dihydroquinazolin-4-One to downstream sectors that require finely controlled intermediates for targeted synthesis. Our technical team works closely with industrial formulators and process engineers to meet strict quality benchmarks across specialty pharmaceutical, crop protection, and advanced material manufacturing. The following sections outline established application scenarios based on real-world integration, including regulatory standards, composition control, process positioning, and end-uses.

1. Synthesis of Antihypertensive Drug Intermediates

Pharmaceutical ingredient manufacturers use this compound as a core scaffold in the synthesis of certain antihypertensive drug intermediates, particularly in the preparation of dihydroquinazoline-based actives. These processes must precisely control purity, traceability, and impurity profiles due to strict GMP requirements for APIs. The raw material is introduced during multi-step synthesis as a building block, undergoing further functionalization based on targeted derivative profiles.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• Ph. Eur. Monographs (where applicable)
• USP General Chapter <795> for pharmaceutical compounding
• EudraLex Volume 4 Annex 13 (EU GMP for APIs)

Typical usage ratio

• Used at 10–30 mol% relative to the final API’s quinazolinone backbone, depending on synthesis route and batch scale. Adjustments reflect targeted yield and impurity limits.

Downstream process integration

• Introduced during the ring-closure stage in multi-step chemical synthesis of antihypertensive API intermediates, followed by purification and subsequent derivatization.

Final product types

• Dihydroquinazoline-based antihypertensive drug intermediates
• Purified API starting materials for tablet, capsule, or injectable dosage forms

2. Intermediate for Agrochemical Active Ingredients

Agrochemical synthesis operations use this compound as an intermediate in the production of quinazolinone-derivative herbicides and fungicides. Regulatory scrutiny requires full documentation of input purity and trace level contaminants, necessitating traceable sourcing and batch-specific QC for all raw material shipments. Researchers favor this scaffold for innovation in new active substances, incorporating it during key ring construction stages.

Industry compliance standards

• FAO/WHO Specifications and Evaluations for Agricultural Pesticides
• ISO 9001:2015 Quality Management Systems (for production traceability)
• REACH Regulation (EC) No 1907/2006 for chemical registration in the EU
• China National Standard GB 2763 Maximum Residue Limits for Pesticides

Typical usage ratio

• Added at 5–15 wt% of the agrochemical active mass depending on the desired functional group load and final efficacy specification.

Downstream process integration

• Input in the core condensation phase during active ingredient synthesis, followed by halogenation, acetylation, or amination based on the targeted pesticide mode of action.

Final product types

• Herbicide and fungicide technical concentrates
• Bulk pesticide active ingredient packages for formulators

3. Precursor in Anti-Inflammatory API Synthesis

Pharmaceutical manufacturers employ this compound as a precursor in the synthesis of selected anti-inflammatory active pharmaceutical ingredients. Its utility lies in providing a robust heterocyclic core for later-stage functionalization. End-users demand strict conformity to pharmacopoeial standards and full certificate-of-analysis transparency for regulatory submissions. Batch-to-batch consistency is critical for reproducibility in pharmaceutical scale-up.

Industry compliance standards

• US FDA 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)
• Japanese Pharmacopoeia (JP) Section for Chemical Intermediates
• WHO GMP Guidelines for Pharmaceutical Products
• ICH Q3A(R2) for Impurities in New Drug Substances

Typical usage ratio

• Introduced at 12–25 mol% of total precursor input; exact proportion determined by the reactivity of downstream substituents selected during process development.

Downstream process integration

• Reacted in cyclization or substitution stages before final side-chain addition and crystallization steps in anti-inflammatory ingredient manufacturing.

Final product types

• Bulk anti-inflammatory API powders
• API intermediates for tablet production

4. Functional Monomer for Specialty Polymer Additives

Producers of specialty polymers use this compound as a functional monomer or co-monomer where enhanced thermal or UV stability is required. Its heteroaromatic structure allows for covalent incorporation into macromolecular chains, imparting resistance to degradation. Applications require compliance with both chemical and polymer industry regulations, and the raw material must consistently meet specification sheets for molecular weight and purity. Typical usage ratios are narrowed by targeted polymer performance characteristics.

Industry compliance standards

• ISO 9001:2015 for quality management in chemical production
• RoHS Directive 2011/65/EU Annex II (for electronics-related polymers)
• EN ISO 1043-1 for polymer coding and designation
• Regulation (EC) No 1907/2006 (REACH) compliance for polymer chemicals

Typical usage ratio

• Incorporated at 1–5 wt% as a co-monomer, with adjustments based on desired final polymer properties such as tensile strength or photostability.

Downstream process integration

• Fed into bulk polymerization or copolymerization steps, prior to compounding and extrusion in the downstream plastics or coatings plant.

Final product types

• High-performance engineering plastics
• UV-stabilized coatings and films
• Photostable specialty resins for electronics encapsulation

5. Fine Chemical Intermediate for Diagnostic Reagent Manufacturing

Diagnostic reagent manufacturers integrate this molecule as a fine chemical intermediate for synthesizing chromogenic or fluorescent markers used in analytical detection systems. The raw material’s controlled substitution pattern offers a consistent foundation for subsequent functionalization with indicator groups. Trace impurities and residual solvents must be documented and controlled under diagnostics QA protocols, and each batch undergoes additional in-house verification prior to downstream modification.

Industry compliance standards

• ISO 13485:2016 Medical devices—Quality management systems for diagnostic reagents
• 21 CFR Part 820 FDA Quality System Regulation
• EN ISO 18113-1 for in vitro diagnostic medical devices labeling
• REACH and CLP chemical safety documentation

Typical usage ratio

• Added at 3–8 mol% of the total chromophore precursor load, depending on indicator group and sensitivity requirements for the diagnostic method.

Downstream process integration

• Functionalized via directed aromatic substitution, then coupled to detection elements before formulation into liquid or solid reagent kits.

Final product types

• Colorimetric and fluorescent reagent components for diagnostic test strips
• Bulk chromogenic intermediates for assay reagent formulation